前病毒HIV DNA测序，以确定是否适合长效注射用卡博特韦/利匹韦林。
Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine.
作者信息
Alagaratnam Jasmini, Kelly Niall, Dustan Simon, Naous Nadia, Nwanbila Modest, Byrne Ruth, Girometti Nicolo, Asboe David, Taylor Graham P, Boffito Marta
机构信息
Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust.
Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London.
出版信息
AIDS. 2025 Jan 1;39(1):95-98. doi: 10.1097/QAD.0000000000004040. Epub 2024 Dec 5.
Abstract
Increasingly, people attending HIV services are requesting long-acting injectable (LAI) antiretroviral treatment (ART). However, without HIV RNA resistance-associated mutation results, individuals are considered unsuitable for LAI ART. We present our experience of sequencing proviral HIV DNA in 30 individuals to inform suitability for LAI ART, of whom 23 were considered suitable. In conclusion, optimization of diagnostic tools such as proviral HIV DNA sequencing to confirm suitability for LAI ART would be a welcome addition.
摘要
越来越多接受艾滋病病毒治疗服务的人要求使用长效注射用抗逆转录病毒疗法（ART）。然而，如果没有艾滋病病毒RNA耐药相关突变结果，个体被认为不适合使用长效注射用抗逆转录病毒疗法。我们介绍了对30名个体进行原病毒艾滋病病毒DNA测序以确定其是否适合长效注射用抗逆转录病毒疗法的经验，其中23人被认为是适合的。总之，优化诊断工具，如原病毒艾滋病病毒DNA测序以确认是否适合长效注射用抗逆转录病毒疗法，将是一项受欢迎的补充。
相似文献
1
Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine.前病毒HIV DNA测序，以确定是否适合长效注射用卡博特韦/利匹韦林。
AIDS. 2025 Jan 1;39(1):95-98. doi: 10.1097/QAD.0000000000004040. Epub 2024 Dec 5.
2
Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South.美国南部育龄妇女中，在卡博特韦/利匹韦林获批时代对长效注射用抗逆转录病毒疗法的兴趣和偏好。
Clin Infect Dis. 2025 Feb 5;80(1):164-167. doi: 10.1093/cid/ciae331.
3
Long-Acting Injectable Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus: A Review.长效注射用抗逆转录病毒疗法治疗人类免疫缺陷病毒：综述
Curr HIV/AIDS Rep. 2025 Apr 23;22(1):31. doi: 10.1007/s11904-025-00741-4.
4
Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.佛罗里达州卫生保健提供者和 HIV 感染者对长效注射用卡替拉韦/利匹韦林用于抗逆转录病毒治疗实施情况的看法。
AIDS Patient Care STDS. 2024 Jun;38(6):275-285. doi: 10.1089/apc.2024.0067. Epub 2024 Apr 30.
5
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.长效注射用卡替拉韦-利匹韦林在撒哈拉以南非洲治疗 HIV 的潜在作用：建模分析。
Lancet Glob Health. 2021 May;9(5):e620-e627. doi: 10.1016/S2214-109X(21)00025-5. Epub 2021 Mar 23.
6
Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.长效注射型抗逆转录病毒疗法在实践中的应用：一项混合方法实施研究，评估在高风险人群和替代低门槛护理场所使用长效注射型抗逆转录病毒疗法的可行性。
AIDS Patient Care STDS. 2024 May;38(5):221-229. doi: 10.1089/apc.2024.0048. Epub 2024 Apr 24.
7
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.长效注射型抗逆转录病毒治疗：乌干达 HIV 感染者及其医护提供者的经验。
BMC Infect Dis. 2024 Aug 28;24(1):876. doi: 10.1186/s12879-024-09748-5.
8
Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.接受长效注射抗逆转录病毒药物长期治疗的HIV感染者的利匹韦林和卡博特韦谷浓度
J Antimicrob Chemother. 2024 May 2;79(5):1126-1132. doi: 10.1093/jac/dkae080.
9
A Universal Approach to Educating Patients with HIV about Long-Acting Injectable Treatment for HIV.一种向感染艾滋病毒患者普及长效注射用艾滋病毒治疗知识的通用方法。
AIDS Behav. 2025 May;29(5):1704-1712. doi: 10.1007/s10461-024-04610-w. Epub 2025 Mar 3.
10
Implementing long-acting injectable cabotegravir and rilpivirine in Africa.在非洲推广长效注射用卡博特韦和利匹韦林。
Lancet Infect Dis. 2024 Oct;24(10):1060-1061. doi: 10.1016/S1473-3099(24)00296-2. Epub 2024 May 28.
本文引用的文献
1
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.非洲病毒学抑制的成人HIV感染者改用长效卡博特韦和利匹韦林（CARES）：一项随机、多中心、开放标签、非劣效性试验的48周结果
Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28.
2
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.2023 年欧洲艾滋病临床学会指南 12.0 重大修订版。
HIV Med. 2023 Nov;24(11):1126-1136. doi: 10.1111/hiv.13542. Epub 2023 Oct 18.
3
Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine.单中心评估并启动HIV感染者使用长效卡博特韦/利匹韦林的经验。
AIDS. 2023 Mar 15;37(4):605-609. doi: 10.1097/QAD.0000000000003446. Epub 2022 Nov 28.
4
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.英国HIV协会2022年成人HIV-1感染者抗逆转录病毒治疗指南
HIV Med. 2022 Dec;23 Suppl 5:3-115. doi: 10.1111/hiv.13446.
5
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.替诺福韦艾拉酚胺/恩曲他滨替诺福韦片在初治 HIV-1 感染成人中的 3 年疗效和安全性
AIDS. 2022 Jan 1;36(1):39-48. doi: 10.1097/QAD.0000000000003070.
6
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.探索长效卡替拉韦和利匹韦林治疗 HIV-1 病毒学失败的预测因素：多变量分析。
AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883.
7
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡博特韦和利匹韦林每 2 个月给药 1 次用于治疗 HIV-1 感染成人（ATLAS-2M）：48 周结果：一项随机、多中心、开放标签、3b 期、非劣效性研究。
Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
8
Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences.分析 HIV-1 pol 下一代序列中的异常和特征性 APOBEC 突变。
PLoS One. 2020 Feb 26;15(2):e0225352. doi: 10.1371/journal.pone.0225352. eCollection 2020.
9
Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment.使用存档的HIV-1前病毒DNA基因型指导抗逆转录病毒治疗调整后的临床结果
Open Forum Infect Dis. 2019 Dec 14;7(1):ofz533. doi: 10.1093/ofid/ofz533. eCollection 2020 Jan.
10
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.替诺福韦艾拉酚胺/拉米夫定固定剂量 2 药方案与继续使用基于替诺福韦艾拉酚胺的 3 或 4 药方案治疗维持人类免疫缺陷病毒 1 型感染者病毒学抑制的疗效和安全性：3 期、随机、非劣效 TANGO 研究。
Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. doi: 10.1093/cid/ciz1243.
Zotero 插件